britain stirs outcry by weighing benefits of drugs versus price the use of cost effectiveness information in coverage policy decisions in the us and the uk stirling bryan ph d university of birmingham uk university of british columbia canada britain stirs outcry by weighing benefits of drugs versus price millions of patients around the world have taken drugs introduced over the past decade to delay the worsening of alzheimer's disease but this year an arm of britain's government health care system relying on some economists number crunching said the benefit isn t worth the cost it issued a preliminary ruling calling on doctors to stop prescribing the drugs the wall street journal november 22 2005 page a1
